A Comprehensive Pharmaceutical Enterprise with Multi-Field
We are committed to the export of several API and intermediates, such as Azathioprine, Mercaptopurine, Ribavirin etc.
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966, and now is a comprehensive modern pharmaceutical enterprise, specializing in the production of pharmaceutical capsules, injections, tablets, APIs, and pharmaceutical intermediates. The company took the lead in carrying out international certification in 1998, and many products have been approved by many countries and regions such as US FDA, EU EMEA, Australia TGA, UK MHRA, Mexico COFEPRIS and so on. As of May 2022, the company has built 9 GMP workshops, 5 chemical laboratories, 1 preparation laboratory, 1 new drug development department, and 1 pilot plant for new product development and production process technique transformation.
At present, the company can produce more than 70 varieties and nearly 100 specifications of drugs. Among them, Azathioprine, Mercaptopurine, and Ribavirin APIs have been certified by the US FDA and EU GMP several times. The sales market covers more than 20 countries and regions in Europe, America, India, South Africa, and Southeast Asia. At the same time, we also produce marine biomedicine 'glucosamine hydrochloride' series for the treatment and prevention of systemic osteoarthritis.
In the future, Cheng Yi Pharma will aim at the largest annual production in Asia of 2,000 tons of glucosamine hydrochloride API and 1000 tons of super fish oil (icosapent ethyl) projects, focusing on the Massive Health Industry. The 'Cheng Yi Pharma Marine Biomedicine Manufacturing Project' with an investment of 10 billion yuan has been basically completed. Among them, the trial production of ultra-high-purity fish oil EPA soft capsule was successful at the end of 2021. Next, we will launch a series of API and soft capsule products successively such as EPA, nervonic acid, etc. to realize the whole process, whole category, and industry chain layout from food to health products to medicine, striving to seize the heights of strategic commanding, empowering enterprise the new value, and accomplishing collectivizing and high-quality development of the company.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance